Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

IMMUNIC, INC. Director's Dealing 2019

Apr 22, 2019

10196_dirs_2019-04-22_1df89f7a-e9d2-4019-af6c-abaa60ba01dc.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: IMMUNIC, INC. (IMUX)
CIK: 0001280776
Period of Report: 2019-04-12

Reporting Person: Vitt Daniel (Director, CEO, President)

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 369177 Indirect

Footnotes

F1: On April 12, 2019, pursuant to an Exchange Agreement, dated as of January 6, 2019, between the Issuer (then known as Vital Therapies, Inc.), Immunic AG ("Immunic"), and the shareholders of Immunic party thereto (the "Exchange Agreement"), the holders of Immunic ordinary shares exchanged all of their outstanding shares for shares of Issuer common stock, resulting in Immunic becoming a wholly-owned subsidiary of the Issuer (the "Transaction"). Immediately following the Transaction, the Issuer changed its name to "Immunic, Inc." In connection with the Transaction, the Reporting Person was appointed Director, Chief Executive Officer and President of the Issuer.

F2: The Reporting Person is Managing Director of Listrax UG (haftungsbeschrankt), which is the record holder of 369,177 shares of common stock of the Issuer, and exercises voting and dispositive power over such shares.